Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans

MPG-Autoren
Es sind keine MPG-Autoren in der Publikation vorhanden
Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)

Aklillu_2013.pdf
(Verlagsversion), 931KB

Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Aklillu, E., Odenthal-Hesse, L., Bowdrey, J., Habtewold, A., Ngaimisi, E., Yimer, G., et al. (2013). CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans. BMC Infectious Diseases, 13: 536. doi:10.1186/1471-2334-13-536.


Zitierlink: https://hdl.handle.net/11858/00-001M-0000-0028-6198-3
Zusammenfassung
Background
The role of copy number variation of the CCL3L1 gene, encoding MIP1α, in contributing to
the host variation in susceptibility and response to HIV infection is controversial. Here we
analyse a sub-Saharan African cohort from Tanzania and Ethiopia, two countries with a high
prevalence of HIV-1 and a high co-morbidity of HIV with tuberculosis.
Methods
We use a form of quantitative PCR called the paralogue ratio test to determine CCL3L1 gene
copy number in 1134 individuals and validate our copy number typing using array
comparative genomic hybridisation and fiber-FISH.
Results
We find no significant association of CCL3L1 gene copy number with HIV load in
antiretroviral-naïve patients prior to initiation of combination highly active anti-retroviral
therapy. However, we find a significant association of low CCL3L1 gene copy number with
improved immune reconstitution following initiation of highly active anti-retroviral therapy
(p = 0.012), replicating a previous study.
Conclusions
Our work supports a role for CCL3L1 copy number in immune constitution following
antiretroviral therapy in HIV, and suggests that the MIP1α -CCR5 axis might be targeted to
aid immune reconstitution.